Table 2 Baseline characteristics of the patients with CD
Variables | All (n = 44) | Vedolizumab | Ustekinumab | p value |
|---|---|---|---|---|
(n = 28, 63.6%) | (n = 16, 36.4%) | |||
Demographic variables | ||||
Age, years | 36.9 (31.3–46.0) | 39.2 (31.9–47.6) | 34.4 (26.1–40.8) | 0.326 |
Male gender | 22 (50.0) | 15 (53.6) | 7 (43.8) | 0.531 |
Body mass index | 18.6 (17.0–20.2) | 18.1 (17.0–19.4) | 19.6 (17.4–22.4) | 0.220 |
Duration from CD diagnosis, year | 21.7 (17.0–28.7) | 22.4 (17.0–28.8) | 19.7 (17.1–24.6) | 0.861 |
Smoking status at diagnosis | 0.220 | |||
Never smoked | 36 (81.8) | 25 (89.3) | 11 (68.7) | |
Ex-smoker | 5 (11.4) | 2 (7.1) | 3 (18.8) | |
Current smoker | 3 (6.8) | 1 (3.6) | 2 (12.5) | |
Previous intestinal resection surgery | 33 (75.0) | 23 (82.1) | 10 (62.5) | 0.169 |
Montreal location | 0.821 | |||
Ileal (L1) | 10 (22.7) | 7 (25.0) | 3 (18.8) | |
Colonic (L2) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
Ileocolonic (L3) | 33 (75.0) | 20 (71.4) | 13 (81.3) | |
Isolated upper GI disease (L4) | 1 (2.3) | 1 (3.6) | 0 (0.0) | |
Montreal disease behavior | 0.007 | |||
Nonstricturing, nonpenetrating (B1) | 13 (29.5) | 4 (14.3) | 9 (56.2) | |
Stricturing (B2) | 12 (27.3) | 11 (39.3) | 1 (6.3) | |
Penetrating (B3) | 19 (43.2) | 13 (46.4) | 6 (37.5) | |
Perianal disease modifier (p) | 33 (75.0) | 21 (75.0) | 12 (75.0) | 1.000 |
Prior anti TNF therapy use | 0.690 | |||
1 | 23 (52.3) | 14 (50.0) | 9 (56.3) | |
≥ 2 | 21 (47.7) | 14 (50.0) | 7 (43.8) | |
Crohn's disease activity index | 0.013 | |||
220 ≤ CDAI < 450 | 40 (90.9) | 28 (100.0) | 12 (75.0) | |
CDAI ≥ 450 | 4 (9.1) | 0 (0.0) | 4 (25.0) | |
Endoscopic disease activity | 0.711 | |||
SES-CD score 3–6 | 14 (31.8) | 10 (38.5) | 4 (26.7) | |
SES-CD score 7–15 | 23 (52.3) | 14 (53.8) | 9 (60.0) | |
SES-CD score > 15 | 4 (9.1) | 2 (7.7) | 2 (13.3) | |
Laboratory variables | ||||
Hemoglobin, g/dL | 10.0 (10.0–11.0) | 10.0 (10.0–10.5) | 10.0 (10.0–12.6) | 0.112 |
Erythrocyte sedimentation rate, mm/h | 44.5 (10.0–102.5) | 33.0 (10.0–102.3) | 68.0 (10.0–102.5) | 0.836 |
Serum C-reactive protein, mg/dL | 0.5 (0.3–4.8) | 0.4 (0.2–1.1) | 0.8 (0.4–10.9) | 0.777 |
Serum albumin, g/dL | 2.5 ± 0.8 | 2.3 ± 0.6 | 2.9 ± 1.0 | 0.026 |
Causes of discontinuation of anti-TNF | 0.482 | |||
Primary non-response | 5 (11.4) | 2 (7.1%) | 3 (18.8%) | |
Secondary non-response | 31 (70.5) | 21 (75.0%) | 10 (62.5%) | |
Adverse event | 8 (18.1) | 5 (17.9%) | 3 (18.8%) | |
Concomitant medication | ||||
Steroid | 27 (61.4) | 20 (71.4) | 7 (43.8) | 0.070 |
Immunomodulator | 30 (68.2) | 16 (57.1) | 14 (87.5) | 0.038 |